<DOC>
	<DOC>NCT00882518</DOC>
	<brief_summary>The primary objective of this study is to evaluate the efficacy of quetiapine fumarate extended-release (XR) used as mono-therapy, administered once daily, in the treatment of schizophrenic patient with acute episode.</brief_summary>
	<brief_title>Efficacy and Safety of Quetiapine Fumarate in the Treatment of Schizophrenic Patients</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<mesh_term>Chlorpromazine</mesh_term>
	<criteria>Schizophrenia diagnosis Provision of written informed consent before initiation of any study AIDS and hepatitis B History of seizure disorder Hospitalisation for schizophrenic more than 1 month immediately before enter into study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Quetiapine Fumarate (SEROQUEL) Extended-Release (XR)</keyword>
	<keyword>qualified PANSS assessment</keyword>
</DOC>